Bayer receives FDA accelerated approval for HER2-mutant lung cancer drug
Bayer received FDA accelerated approval for sevabertinib as a first-line treatment for advanced HER2-mutant non-small cell lung cancer patients, after priority review and breakthrough therapy status.